Last updated on July 2018

Safety Tolerability and Pharmacokinetics Study of Turoctocog Alfa Pegol Injected Under the Skin in Patients With Haemophilia A


Brief description of study

The trial is conducted in Asia, Europe and North America. The aim of the study is to evaluate the safety of administration under the skin of turoctocog alfa pegol (SC N8-GP) in patients with severe haemophilia A.

Clinical Study Identifier: NCT02994407

Contact Investigators or Research Sites near you

Start Over

Novo Nordisk

Novo Nordisk Investigational Site
Orlando, FL United States

Novo Nordisk

Novo Nordisk Investigational Site
East Lansing, MI United States

Novo Nordisk

Novo Nordisk Investigational Site
Cleveland, OH United States

Novo Nordisk

Novo Nordisk Investigational Site
Dayton, OH United States

Novo Nordisk

Novo Nordisk Investigational Site
Charleston, SC United States

Novo Nordisk

Novo Nordisk Investigational Site
Milwaukee, WI United States

Novo Nordisk

Novo Nordisk Investigational Site
Innsbruck, Austria

Novo Nordisk

Novo Nordisk Investigational Site
Wien, Austria

Novo Nordisk

Novo Nordisk Investigational Site
Nantes Cedex 1, France

Novo Nordisk

Novo Nordisk Investigational Site
Berlin, Germany

Novo Nordisk

Novo Nordisk Investigational Site
Duisburg, Germany

Novo Nordisk

Novo Nordisk Investigational Site
Homburg, Germany

Novo Nordisk

Novo Nordisk Investigational Site
Shinjuku-ku, Tokyo, Japan

Novo Nordisk

Novo Nordisk Investigational Site
Suginami-ku, Tokyo, Japan

Novo Nordisk

Novo Nordisk Investigational Site
Belgrade, Serbia

Novo Nordisk

Novo Nordisk Investigational Site
Novi Sad, Serbia

Novo Nordisk

Novo Nordisk Investigational Site
Iowa City, IA United States

Novo Nordisk

Novo Nordisk Investigational Site
Norfolk, VA United States